Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, ...

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company ...

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...

Verona Pharma isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are ...

In a report released today, Thomas Shrader from BTIG maintained a Buy rating on Verona Pharma (VRNA – Research Report), with a price ...

Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ETCompany ParticipantsDavid Zaccardelli - President and ...

At the close in NYSE,... ByInvesting.com • Mar 26, 2018 Verona Pharma's RPL554 shows treatment effect in mid-stage CF study; shares up 8% A UK-based Phase 2a clinical trial evaluating Verona ...

Get Our Latest Analysis on VRNA Verona Pharma Trading Down 1.7 % Shares of Verona Pharma stock opened at $33.86 on Monday. The company has a current ratio of 8.61, a quick ratio of 8.61 and a debt ...

Verona Pharma (NASDAQ:VRNA) is scheduled to announce Q3 earnings results on Monday, November 4th, before market open. The consensus EPS Estimate is -$0.41 and the consensus Revenue Estimate is $2.01M.

CEO David Zaccardelli sold 4,800 shares of Verona Pharma stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $4.38, for a total transaction of ...

Mark W. Hahn, the Chief Financial Officer of Verona Pharma plc (NASDAQ:VRNA), recently executed significant stock sales as reported in a filing with the Securities and Exchange Commission. On October ...